CAJ | 학술논문

为了解89SrCl2治疗转移性骨肿瘤的应用价值和不良反应，根据89SrCl2治疗适应征,25例恶性肿瘤骨转移患者采用静脉注射89SrCl2 1.48—2.22MBq/kg(体重),治疗后每2周测定白细胞、血小板计数和血生化肝、肾功能指标,连续8—12周。随访观察患者骨痛的缓解情况和不良反应,并进行评判。结果表明，25例中显效4例,有效14例,无效7例。前列腺癌、乳癌骨痛缓解疗效较高(分别为4/4和6/8),总有效率为72%(18/25)。重复治疗仍有疗效 (6/6)。疼痛缓解起始时间为2—14d,缓解持续时间达12—36周。有轻度骨髓抑制反应,血液学毒性小于Ⅱ级,肝、肾功能血生化指标无明显变化,未见出血、胃肠道不适、过敏等不良反应。少数患者(5/25)有骨痛闪烁现象。无效可能与多种因素有关。实验结果说明，89SrCl2治疗转移性骨肿瘤对缓解患者的骨痛症状和改善生活质量不失为一种有效、安全的手段,值得临床推广应用。
위료해89SrCl2치료전이성골종류적응용개치화불량반응，근거89SrCl2치료괄응정,25례악성종류골전이환자채용정맥주사89SrCl2 1.48—2.22MBq/kg(체중),치료후매2주측정백세포、혈소판계수화혈생화간、신공능지표,련속8—12주。수방관찰환자골통적완해정황화불량반응,병진행평판。결과표명，25례중현효4례,유효14례,무효7례。전렬선암、유암골통완해료효교고(분별위4/4화6/8),총유효솔위72%(18/25)。중복치료잉유료효 (6/6)。동통완해기시시간위2—14d,완해지속시간체12—36주。유경도골수억제반응,혈액학독성소우Ⅱ급,간、신공능혈생화지표무명현변화,미견출혈、위장도불괄、과민등불량반응。소수환자(5/25)유골통섬삭현상。무효가능여다충인소유관。실험결과설명，89SrCl2치료전이성골종류대완해환자적골통증상화개선생활질량불실위일충유효、안전적수단,치득림상추엄응용。
To evaluate the safety and efficacy of 89SrCl2 in the treatment of painful skeletal metastases of cancer patients. 25 metastatic bony pain patients received 1.48—2.22MBq/kg 89SrCl2 intraveneously. After therapy the white blood cell, platelet count, liver and renal function was measured every two weeks during 8—12 weeks. The pain relier and adverse effect were also observed and dose was carried out after 3 months or re-occurrence of pain. Results shown that, pain relief was observed in 18 of 25 patients, among them, complete relief in 4, improved in 14 and no relief in 7. The bony pain responded well in prostate cancer and breast cancer (4/4 and 6/8 respectively), and also effective in repeat treatment (6/6). Pain relief begin from 2—14 days and the duration of pain relief was 12—36 weeks. The toxicity was mild, only transient and restricted to hematological toxicity (<grade II). No adverse reaction, such as bleeding, gastrointestinal symptom and anaphylaxis had been found 5 of 25 patients had pain flar. Conclusions 89SrCl2 was an pain-relief agent for skeletal metastases. It can improve the quality of life in the patients and was sate and valuable for clinical use.